PMC:6640909 / 70777-71260 JSONTXT

{"project":"TEST0","denotations":[{"id":"31100109-100-106-7556","span":{"begin":100,"end":102},"obj":"[\"16198246\"]"},{"id":"31100109-192-199-7557","span":{"begin":192,"end":195},"obj":"[\"28461796\"]"},{"id":"31100109-207-214-7558","span":{"begin":405,"end":408},"obj":"[\"25298334\"]"},{"id":"31100109-67-74-7559","span":{"begin":478,"end":481},"obj":"[\"28982652\"]"}],"text":"Diabetes is common in recipients of LT-MCS (43%) but, in contrast to results from a previous study [28], does not increase mortality or serious adverse event rates during LT-MCS support [112, 113]. In a retrospective analysis (n = 244), LT-MCS therapy was associated with improvement in diabetic control that was attributed to improvements in cardiac output and normalization of biochemical derangements [114]. More awareness of diabetic patients with advanced HF is necessary [115]."}

{"project":"MyTest","denotations":[{"id":"31100109-16198246-28905616","span":{"begin":100,"end":102},"obj":"16198246"},{"id":"31100109-28461796-28905617","span":{"begin":192,"end":195},"obj":"28461796"},{"id":"31100109-25298334-28905618","span":{"begin":405,"end":408},"obj":"25298334"},{"id":"31100109-28982652-28905619","span":{"begin":478,"end":481},"obj":"28982652"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Diabetes is common in recipients of LT-MCS (43%) but, in contrast to results from a previous study [28], does not increase mortality or serious adverse event rates during LT-MCS support [112, 113]. In a retrospective analysis (n = 244), LT-MCS therapy was associated with improvement in diabetic control that was attributed to improvements in cardiac output and normalization of biochemical derangements [114]. More awareness of diabetic patients with advanced HF is necessary [115]."}

{"project":"0_colil","denotations":[{"id":"31100109-16198246-7556","span":{"begin":100,"end":102},"obj":"16198246"},{"id":"31100109-28461796-7557","span":{"begin":192,"end":195},"obj":"28461796"},{"id":"31100109-25298334-7558","span":{"begin":405,"end":408},"obj":"25298334"},{"id":"31100109-28982652-7559","span":{"begin":478,"end":481},"obj":"28982652"}],"text":"Diabetes is common in recipients of LT-MCS (43%) but, in contrast to results from a previous study [28], does not increase mortality or serious adverse event rates during LT-MCS support [112, 113]. In a retrospective analysis (n = 244), LT-MCS therapy was associated with improvement in diabetic control that was attributed to improvements in cardiac output and normalization of biochemical derangements [114]. More awareness of diabetic patients with advanced HF is necessary [115]."}

{"project":"2_test","denotations":[{"id":"31100109-16198246-28905616","span":{"begin":100,"end":102},"obj":"16198246"},{"id":"31100109-28461796-28905617","span":{"begin":192,"end":195},"obj":"28461796"},{"id":"31100109-25298334-28905618","span":{"begin":405,"end":408},"obj":"25298334"},{"id":"31100109-28982652-28905619","span":{"begin":478,"end":481},"obj":"28982652"}],"text":"Diabetes is common in recipients of LT-MCS (43%) but, in contrast to results from a previous study [28], does not increase mortality or serious adverse event rates during LT-MCS support [112, 113]. In a retrospective analysis (n = 244), LT-MCS therapy was associated with improvement in diabetic control that was attributed to improvements in cardiac output and normalization of biochemical derangements [114]. More awareness of diabetic patients with advanced HF is necessary [115]."}